Cantourage Group SE Enhances Profitability Amid Pricing Challenges

Cantourage Group SE reported a significant improvement in profitability for Q3 2026 despite facing increased pricing pressure in the German market. Revenue slightly decreased to EUR 19.9 million from EUR 20.3 million the previous year, yet the gross margin improved to 35.3% from 18.1%. The EBITDA rose from EUR –2.2 million in Q3 2025 to EUR 1.9 million, reflecting a strengthened EBITDA margin of 9.5%. The company attributes these positive changes to a strategic focus on high-value products and market diversification across Europe.

The international operations contributed over half of the group's revenue, highlighting a reduced dependence on the German market. The UK and Poland were significant contributors, with revenues of EUR 9.3 million and EUR 1.1 million, respectively. In Germany, competitive pressure required a focus on premium products rather than sheer volume growth.

Cantourage's strategic initiatives include securing exclusive supply agreements and expanding its product portfolio with new active ingredients. Further, the development of Telecan highlights their commitment to strengthening their role in the healthcare ecosystem.